Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 1
1949 1
1950 2
1952 3
1954 3
1955 1
1956 2
1957 9
1958 2
1959 5
1960 4
1961 4
1962 3
1963 2
1964 10
1965 10
1966 7
1967 6
1968 7
1969 10
1970 5
1971 19
1972 11
1973 17
1974 8
1975 19
1976 18
1977 14
1978 13
1979 12
1980 15
1981 21
1982 19
1983 21
1984 24
1985 16
1986 23
1987 17
1988 21
1989 28
1990 23
1991 27
1992 14
1993 23
1994 28
1995 20
1996 26
1997 25
1998 22
1999 36
2000 33
2001 36
2002 34
2003 22
2004 42
2005 57
2006 36
2007 53
2008 57
2009 82
2010 81
2011 111
2012 103
2013 140
2014 162
2015 156
2016 150
2017 135
2018 146
2019 141
2020 165
2021 159
2022 133
2023 16
Text availability
Article attribute
Article type
Publication date

Search Results

2,618 results
Results by year
Filters applied: . Clear all
Page 1
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Powles T, et al. Among authors: rosenberg je. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12. N Engl J Med. 2021. PMID: 33577729 Free PMC article. Clinical Trial.
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Samstein RM, et al. Among authors: rosenberg j. Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14. Nat Genet. 2019. PMID: 30643254 Free PMC article.
Treatment Options for Abdominal Rectus Diastasis.
Jessen ML, Öberg S, Rosenberg J. Jessen ML, et al. Among authors: rosenberg j. Front Surg. 2019 Nov 19;6:65. doi: 10.3389/fsurg.2019.00065. eCollection 2019. Front Surg. 2019. PMID: 31803753 Free PMC article. Review.
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR, Holm JS, Rosenberg JE, Shah SP, Vázquez-García I, Weigelt B, Wu M, Zamarin D, Campitelli LF, Osborne EJ, Klinger M, Robins HS, Khincha PP, Savage SA, Balachandran VP, Wolchok JD, Hellmann MD, Merghoub T, Levine AJ, Łuksza M, Greenbaum BD. Hoyos D, et al. Among authors: rosenberg je. Nature. 2022 Jun;606(7912):172-179. doi: 10.1038/s41586-022-04696-z. Epub 2022 May 11. Nature. 2022. PMID: 35545680 Free PMC article.
In Reply.
Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Lacouture ME, et al. Among authors: rosenberg je. Oncologist. 2022 Oct 1;27(10):e827-e828. doi: 10.1093/oncolo/oyac171. Oncologist. 2022. PMID: 36036599 Free PMC article.
The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M, Rosenberg JE. Lattanzi M, et al. Among authors: rosenberg je. Expert Rev Anticancer Ther. 2020 Jul;20(7):551-561. doi: 10.1080/14737140.2020.1782201. Epub 2020 Jul 21. Expert Rev Anticancer Ther. 2020. PMID: 32552213 Free PMC article. Review.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. Yuen KC, et al. Among authors: rosenberg je. Nat Med. 2020 May;26(5):693-698. doi: 10.1038/s41591-020-0860-1. Epub 2020 May 11. Nat Med. 2020. PMID: 32405063 Free PMC article.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group. Bellmunt J, et al. Among authors: rosenberg je. Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721560 Free PMC article. Clinical Trial.
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.
Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME. Phillips GS, et al. Among authors: rosenberg je. J Clin Oncol. 2019 Oct 20;37(30):2746-2758. doi: 10.1200/JCO.18.02141. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216228 Free PMC article.
2,618 results